TMCnet News
Mitomics signs agreement with QDx Pathology ServicesMay 20, 2011 (Datamonitor Financial Deals Tracker via COMTEX) -- Mitomics, Inc., a Canada-based company engaged in research and development of mitochondrial genome-based products, has signed a non-exclusive license agreement with QDx Pathology Services, Inc., a US-based independent clinical and anatomic pathology laboratory engaged in providing diagnostic excellence. Under the partnership, QDx Pathology Services will develop, market and process QPredict(TM) prostate mitomic test which will be based on the mitochondrial marker behind Mitomics' Prostate Core Mitomic Test(TM) (PCMT). QDx will leverage its existing network of urologists, pathologists and processing centers to expand the availability of the technology across the US. Deal Type Partnership Sub-Category Development,Marketing,Licensing Agreement Deal Status Announced: 2011-05-19 Deal Participants Partner 1 (Company) Mitomics, Inc. Partner 2 (Company) QDx Pathology Services, Inc. |